You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for silver sulfadiazine


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for silver sulfadiazine

Vendor Vendor Homepage Vendor Sku API Url
Hangzhou Trylead Chemical Technology ⤷  Start Trial TL8001845 ⤷  Start Trial
NovoSeek ⤷  Start Trial 5459124 ⤷  Start Trial
NovoSeek ⤷  Start Trial 441244 ⤷  Start Trial
NovoSeek ⤷  Start Trial 452254 ⤷  Start Trial
ISpharm ⤷  Start Trial I06-145 ⤷  Start Trial
ISpharm ⤷  Start Trial I06-0145 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for Silver Sulfadiazine

Last updated: February 19, 2026

What are the leading suppliers of bulk silver sulfadiazine API?

Silver sulfadiazine API is primarily used in topical antimicrobial formulations, especially burns treatment. The manufacturing and sourcing landscape includes several key regions and companies.

Major manufacturing regions

Region Companies and Countries Details
China Zhejiang Hisun Pharmaceutical Co., Ltd.; Zhejiang, China Large-scale production, competitive pricing, regulated by NMPA
India Jubilant Life Sciences; Sun Pharma; Biocon Focused on generic APIs, GMP-compliant manufacturing sites
Europe Synthesis with facilities in Germany, Italy Mostly for high-quality, regulatory-compliant supply
United States Privately held companies; smaller scale production Limited domestic production, relies on imports

Key suppliers of bulk silver sulfadiazine API

Company Name Location Certification Production Capacity Notes
Zhejiang Hisun Pharmaceutical Zhejiang, China cGMP, ISO 9001 50+ tons/year Major supplier for global demand
Jubilant Life Sciences Uttar Pradesh, India cGMP, ISO 9001 20+ tons/year Tier-one supplier for global generics
Piramal Pharma Solutions Maharashtra, India cGMP, ISO 9001 10+ tons/year Focused on quality, small batch production
Synthesis (Europe) Europe (Germany, Italy) EUGMP, ISO 9001 5+ tons/year Usually for high-value markets

Supply chain considerations

  • Regulatory compliance: Manufacturers with certifications like cGMP, ISO 9001 are preferred.
  • Pricing: Chinese suppliers generally offer lower costs because of scale.
  • Quality verification: European suppliers tend to meet stringent testing standards, suitable for highly regulated markets.
  • Availability: Manufacturing capacity fluctuates based on regional demand and global supply chain disruptions.

Sourcing trends and challenges

  • Quality control: Differentiates suppliers. Key for contracts requiring regulatory approval.
  • Price competition: Chinese suppliers capture most of the market share due to cost advantages.
  • Supply constraints: Disrupted by geopolitical issues, pandemic-related manufacturing delays, and raw material shortages.
  • Regulatory barriers: Suppliers must adhere to regional Good Manufacturing Practice (GMP) standards to serve developed markets like the US and EU.

Summary of key APIs sources

Supplier Region Production Focus Certification Market Share Dominance Known for
China Cost-effective bulk API cGMP, ISO Large Cost and quantity
India Quality, volume flexibility cGMP, ISO Moderate Cost and quality balance
Europe High compliance, quality EUGMP, ISO Low to moderate Quality, regulatory focus
US Niche, high compliance cGMP Small High-value, regulatory

Final notes

Decisions on API sourcing involve balancing price, quality, regulatory compliance, and supply reliability. Chinese and Indian suppliers dominate volume, while European and US suppliers focus on quality and regulatory standards.


Key Takeaways

  • China remains the largest supplier of bulk silver sulfadiazine API, offering competitive pricing and high volume.
  • Indian manufacturers balance price and quality, with GMP compliance suited for global markets.
  • European and US suppliers focus on quality, meeting stringent regulatory standards but on smaller scales.
  • Supply chain disruptions impact availability, emphasizing the importance of supplier diversification.
  • Regulatory certification significantly influences supplier choice in developed markets.

FAQs

1. What certifications should I verify when sourcing silver sulfadiazine API?
Look for cGMP, ISO 9001, or EUGMP certificates. These assure quality management and regulatory compliance.

2. How does pricing differ between regions?
Chinese suppliers offer the lowest costs due to economies of scale. Indian suppliers offer a middle ground with a focus on balancing cost and quality.

3. Are there potential import restrictions for Chinese APIs in US and EU markets?
Yes. US FDA and EU EMA regulate imported APIs. Suppliers must meet regional standards and submit proper documentation.

4. How reliable are regional supply chains?
Chinese suppliers have high capacity but may face geopolitical or logistical issues. Indian suppliers have similar risks but often maintain diversified manufacturing sites.

5. Can high-quality European suppliers meet global demand?
They can, but their capacity is limited compared to Asian suppliers. They primarily serve markets requiring strict regulatory adherence.


References

[1] Food and Drug Administration (FDA). (2022). API Manufacturer Approval Process. FDA.gov.
[2] European Medicines Agency (EMA). (2022). Guidelines on Good Manufacturing Practices. EMA.europa.eu.
[3] Worldwide Market for Active Pharmaceutical Ingredients (API). (2023). IQVIA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.